Kevin G. Peters
Chief Tech/Sci/R&D Officer chez Aerpio Therapeutics, Inc.
Profil
Kevin G.
Peters is currently the Chief Scientific Officer at Aerpio Therapeutics, Inc. He previously worked as the Group Medical Director at Bristol Myers Squibb Co., Head-Therapeutic Angiogenesis Research at Procter & Gamble Pharmaceuticals, Inc., Associate Professor-Medicine & Pharmacology at Duke University Medical Center, and CSO, Vice President-Research & Development at Akebia Therapeutics, Inc. He was also the Chief Scientific & Medical Officer at Aerpio Pharmaceuticals, Inc. from 2019 to 2021.
Peters received his undergraduate degree from Augustana University and his doctorate from the University of Iowa.
Postes actifs de Kevin G. Peters
Sociétés | Poste | Début |
---|---|---|
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Kevin G. Peters
Sociétés | Poste | Fin |
---|---|---|
AERPIO PHARMACEUTICALS | Chief Tech/Sci/R&D Officer | 31/03/2021 |
Duke University Medical Center | Corporate Officer/Principal | - |
BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | - |
Procter & Gamble Pharmaceuticals, Inc.
Procter & Gamble Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Procter & Gamble Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its products include Actonel, Asacol, Enablex, Didronel, Macrobid, Macrodantin, Entex, and Ziac. The firm manufactures and markets a variety of over-the-counter and oral care products such as Crest, Oral-B, Prilosec OTC, Vicks, Metamucil, Pepto-Bismol, ThermaCare, and other related products. The company was founded in 1970 and is headquartered in Cincinnati, OH. | Chief Tech/Sci/R&D Officer | - |
AKEBIA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Kevin G. Peters
Augustana University | Undergraduate Degree |
University of Iowa | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
AKEBIA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Procter & Gamble Pharmaceuticals, Inc.
Procter & Gamble Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Procter & Gamble Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its products include Actonel, Asacol, Enablex, Didronel, Macrobid, Macrodantin, Entex, and Ziac. The firm manufactures and markets a variety of over-the-counter and oral care products such as Crest, Oral-B, Prilosec OTC, Vicks, Metamucil, Pepto-Bismol, ThermaCare, and other related products. The company was founded in 1970 and is headquartered in Cincinnati, OH. | Health Technology |
Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |